Henry Schein (HSIC) Reports Q2: Everything You Need To Know Ahead Of Earnings - The Chronicle-Journal
Article excerpt
Highlighted: the sentence this signal was extracted from
Dental and medical products company Henry Schein ( NASDAQ: HSIC ) will be reporting results this Tuesday before the bell. Here's what you need to know. Henry Schein beat analysts' revenue expectations last quarter, reporting revenues of $3.37 billion, up 6.3% year on year. It was a mixed quarter for the company, with a beat of analysts' EPS estimates but full-year EPS guidance in line with analysts' estimates. Is Henry Schein a buy or sell going into earnings? Read our full analysis here, it's free for active Edge members. This quarter, the market is expecting Henry Schein's revenue to grow 4.1% year on year, in line with the 3.3% increase it recorded in the same quarter last year. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Henry Schein has missed Wall Street's revenue estimates multiple times over the last two years. Looking at Henry Schein's peers in the healthcare equipment and supplies segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Align Technology delivered year-on-year revenue growth of 4.3%, meeting analysts' expectations, and Baxter reported revenues up 5.3%, topping estimates by 6%. Align Technology's stock price was unchanged after the resultswhile Baxter was up 5.7%. Read our...
Keep reading with a free account
The rest of this article, and every signal for Henry Schein, is in your free account.